ENDOCYTE INC
- Headquarters
- WEST LAFAYETTE, IN
- Latest Form D
- $8.1M, Dec 2010
- Total capital
- $30.8M
- Federal grants
- $3.8M
- 12 awards · 1997–2003
- Private capital raised
- $27M
- 2 Form D · last Dec 2010
- 190 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 16
- 24 pending · first 2019
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$8.1M
- Private capital raisedForm D · SEC · 1st filing$18.9M
- Federal grantHealth and Human S · Phase I · Folate Targeted Delivery of a CDKI$124K
- Federal grantHealth and Human S · Phase II · *Enhancement of tumor targeting and chemotherapeutic ac*$640K
- Federal grantHealth and Human S · Phase II · Tumor targeting and chemotherapy with folate-conjugates$593K
- Federal grantHealth and Human S · Phase I · Development of Tumor-Targeted Drug Conjugates$250K
- Federal grantHealth and Human S · Phase II · *Enhancement of tumor targeting and chemotherapeutic ac*$392K
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase II · A Folate Targeted 99M-TC Diagnostic Imaging Agent$156K
- Federal grantHealth and Human S · Phase II · A Folate Targeted 99M-TC Diagnostic Imaging Agent$643K
- Federal grantHealth and Human S · Phase I · Targeted 99M Tc Radiopharmaceutical For Tumor Imaging$100K
- Federal grantHealth and Human S · Phase II · Novel Targeted Radiopharmaceutical For Tumor Imaging$359K
- Federal grantHealth and Human S · Phase II · Novel Targeted Radiopharmaceutical For Tumor Imaging$89K
- Federal grantHealth and Human S · Phase II · Novel Targeted Radiopharmaceutical For Tumor Imaging$391K
- Federal grantHealth and Human S · Phase I · Novel Targeted Radiopharmaceutical For Tumor Imaging$100K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
150months
from ENDOCYTE INC’s first federal award to its first private round.
- First federal award · Jan 1997
- Health and Human S · $100K
- First Form D · Aug 2009
- $18.9M · 1st Form D
- Awards before first raise
- 12 awards
An association in public records, not a cause or a prediction.
Founders and team
From SEC Form D filings- Ann F. HanhamDirectorNamed in SEC Form D filings
- Douglas B. BaileyDirectorNamed in SEC Form D filings
- Fred A. MiddletonDirectorNamed in SEC Form D filings
- Jack ClawsonDirectorNamed in SEC Form D filings
- James S. ShannonDirectorNamed in SEC Form D filings
- John C. AplinDirectorNamed in SEC Form D filings
Show all 12 people
- John C. ClawsonDirectorNamed in SEC Form D filings
- Keith E. BrauerDirectorNamed in SEC Form D filings
- Michael A. ShermanExecutive OfficerNamed in SEC Form D filings
- Mike ShermanExecutive OfficerNamed in SEC Form D filings
- Philip S. LowDirectorNamed in SEC Form D filings
- P. Ron EllisExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 16 granted of 40- PendingMethod Of Treating Psma-expressing CancersUSPTOApplication 19538457
- PendingMethods For Preparing Psma ConjugatesUSPTOApplication 19374943
- GrantedMethods For Preparing Psma ConjugatesUSPTOUS 12,473,265
Show all 40 patent records
- Method Of Treating Psma-expressing CancersJun 25, 2026 · Application 19538457Pending
- Methods For Preparing Psma ConjugatesApr 16, 2026 · Application 19374943Pending
- Methods For Preparing Psma ConjugatesNov 18, 2025 · US 12,473,265Granted
- Methods Of Treating CancerJul 24, 2025 · Application 18999436Pending
- Conjugates For Treating Diseases Caused By Psma Expressing CellsMay 29, 2025 · Application 18906001Pending
- Methods Of Treating CancerJan 28, 2025 · US 12,208,102Granted
- Methods And Compositions For Car T Cell TherapyNov 19, 2024 · US 12,144,850Granted
- Compositions And Methods For Car T Cell TherapyMay 23, 2024 · Application 18494613Pending
- Compositions And Methods For Car T Cell TherapyDec 26, 2023 · US 11,850,262Granted
- Method Of Treating Psma-expressing CancersMar 30, 2023 · Application 17904442Pending
- Conjugates For Treating Diseases Caused By Psma Expressing CellsAug 25, 2022 · Application 17737471Pending
- Folate Receptor Binding Conjugates of AntifolatesJan 11, 2022 · US 11,219,622Granted
- Shielding Agents And Their UseOct 21, 2021 · Application 17277806Pending
- Conjugates For Treating Diseases Caused By Psma Expressing CellsMay 27, 2021 · Application 17165154Pending
- Conjugates For Treating Diseases Caused By Psma Expressing CellsMay 27, 2021 · Application 17165149Pending
- Antifolate Conjugates For Treating InflammationMar 11, 2021 · Application 16930590Pending
- Bivalent Linkers And Conjugates ThereofMar 4, 2021 · Application 16851745Pending
- Conjugates For Treating Diseases Caused By Psma Expressing CellsFeb 9, 2021 · US 10,912,840Granted
- Conjugates Containing Hydrophilic Spacer LinkersJan 28, 2021 · Application 16919919Pending
- Conjugates For ImagingJan 26, 2021 · US 10,898,596Granted
- Carbonic Anhydrase Ix Inhibitor Conjugates And Uses ThereofDec 8, 2020 · US 10,857,234Granted
- Pbd Conjugates For Treating DiseasesOct 15, 2020 · Application 16088986Pending
- Conjugates For Treating DiseasesSep 17, 2020 · Application 16825566Pending
- Conjugates Containing Hydrophilic Spacer LinkersAug 11, 2020 · US 10,738,086Granted
- Vitamin Receptor Drug Delivery Conjugates For Treating InflammationMay 21, 2020 · Application 16682200Pending
- Bivalent Linkers And Conjugates ThereofMay 12, 2020 · US 10,647,676Granted
- Drug Delivery Conjugates Containing Unnatural Amino Acids And Methods For UsingApr 23, 2020 · Application 16549247Pending
- Conjugates For Treating DiseasesApr 21, 2020 · US 10,624,972Granted
- Folate Conjugate For Use In Targeting Tumor Associated MacrophagesFeb 6, 2020 · Application 16498071Pending
- CCK2R-DRUG ConjugatesDec 10, 2019 · US 10,500,286Granted
- Vitamin Receptor Drug Delivery Conjugates For Treating InflammationDec 10, 2019 · US 10,500,204Granted
- Conjugates For Treating Diseases Caused By Psma Expressing CellsOct 17, 2019 · Application 16423559Pending
- Method Of Imaging With A Chelating AgentSep 24, 2019 · US 10,420,850Granted
- Folate Receptor Binding Conjugates of AntifolatesJul 30, 2019 · US 10,363,250Granted
- Method Of Treating Cancer By Targeting Myeloid-derived Suppressor CellsJul 18, 2019 · Application 16302912Pending
- Vitamin-Receptor Binding Drug Delivery ConjugatesApr 11, 2019 · Application 15936393Pending
- Bivalent Linkers And Conjugates ThereofApr 4, 2019 · Application 16155348Pending
- Conjugates For ImagingJan 29, 2019 · US 10,188,759Granted
- Conjugates For Treating Diseases Caused By Psma Expressing CellsOct 11, 2018 · Application 15989708Pending
- Antifolate Conjugates For Treating InflammationOct 4, 2018 · Application 15570605Pending
Recent research by its founders
- Abstract 4303: AZD2284: A novel, alpha-particle emitting radioconjugate targeting STEAP2 in metastatic castration-resistant prostate cancer20250 cites
- Abstract 5045: NTSR1-targeted alpha therapeutic [Ac-225]-FPI-2059 induces growth inhibition in a preclinical colorectal tumor model20231 cites
- Abstract 5041: TEM-1 targeted alpha therapeutic [Ac-225]-FPI-1848 induces regression in pre-clinical sarcoma xenograft models20230 cites
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .